1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
5
Active Trials
200 recruiting
9
Rare Diseases
across 16 areas
0
News (30d)
Quiet
LMU Klinikum AöR is a company with 1 orphan drug designation across 9 rare diseases. Active clinical trials in 5 indications. 2 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| amyotrophic lateral sclerosis | - | Des.TrialAppr. |
| cardiovascular disorder | - | Des.TrialAppr. |
| epilepsy | - | Des.TrialAppr. |
| gastrointestinal tuberculosis | 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one | Des.TrialAppr. |
| hepatic tuberculosis | 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one | Des.TrialAppr. |
| mitochondrial disease | - | Des.TrialAppr. |
| muscular dystrophy | - | Des.TrialAppr. |
| spinal muscular atrophy | - | Des.TrialAppr. |
| tuberculosis | 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
45
overlap in 2+ diseases
0/9
candidate diseases
0
avg importance: 0
2
affecting portfolio
0% of portfolio targets high unmet need diseases
45
overlap in 2+ diseases
0/9
candidate diseases
0
avg importance: 0
2
affecting portfolio